logo
logo

Taysha Gene Therapies Launches with $30 Million Seed Financing and Unrivaled Strategic Partnership with the UT Southwestern Gene Therapy Program

Apr 29, 2020•about 5 years ago

Amount Raised

$30 Million

Round Type

seed

Dallas

Description

Taysha Gene Therapies today announced it has launched with a mission to eradicate severe and life-threatening monogenic diseases of the central nervous system (CNS) by advancing its pipeline of 15 AAV (adeno-associated virus) gene therapy programs, with options to an additional four programs. The company reunites former investors and executives from AveXis, while accelerating its discovery and development efforts with the UT Southwestern Gene Therapy Program and Department of Pediatrics, one of the largest pediatric neurology residency programs in the U.S.

Company Information

Company

Taysha Gene Therapies With And

Location

Dallas, Georgia, United States

About

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for new cures—to dramatically improve patients’ lives. More information is available at www.tayshagtx.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People